Craig-Hallum recommends using the post-earnings weakness in shares of GeneDx (WGS) as a buying opportunity. The stock is down over 25% following a “modest” Q1 exome and genome volume miss, which is the company’s first ever sequential decline in volumes, the analyst tells investors in a research note. The firm says management noted Q1 volumes were negatively impacted by significantly worse than expected weather impacts as well as one less day. Encouragingly, GeneDx also saw accelerating volumes in March, with strong momentum into Q2, says Craig-Hallum. It believes the company’s exome and genome volume growth will accelerate as the year progresses. The firm reiterates a Buy rating on the shares with a $114 price target The stock in morning trading is down 41%, or $47.56, to $69.41 in morning trading.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on WGS:

Disclaimer & DisclosureReport an Issue

GeneDx earnings selloff a buying opportunity, says Craig-Hallum GeneDx reports Q1 EPS (23c), consensus 9c GeneDx raises 2025 revenue view to $360M-$375M from $350M-$360M GeneDx Holdings Acquires Fabric Genomics for $33 Million GeneDx to acquire Fabric Genomics for $33M in cash at closing

View Comments